Pharmaceutical

Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434

06/23/2022

– Study evaluates pre-administration of cold antibody prior to administration of imaging agent – Imaging shows favorable gain in tumor lesion uptake versus normal tissue when cold antibody is pre-administered – Data presented at the SNMMI 2022 Annual Meeting Excerpt from the Press Release: HAMILTON, ON and BOSTON, June 14, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc.…

Read More

Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413

06/22/2022

KT-333 is a first-in-class heterobifunctional degrader of the transcriptional regulator STAT3 in development for T cell malignancies and solid tumors KT-413 is a first-in-class degrader of IRAK4 and the IMiD substrates Ikaros and Aiolos in development for MYD88-mutant B cell lymphomas  Initial safety and proof-of-mechanism clinical data for both programs to be shared in second…

Read More

Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma

06/22/2022

Investigational New Drug Application Submitted by Omega Represents the First Epigenomic Controller in a New Class of Programmable mRNA Therapeutics Excerpt from the Press Release: CAMBRIDGE, Mass., June 15, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug…

Read More

HUYABIO INTERNATIONAL ANNOUNCES INITIATION OF HBI-3000 PHASE 2 TRIAL

06/21/2022

Excerpt from the Press Release: SAN DIEGO, June 14, 2022 /PRNewswire/ — HUYABIO International today announced that the first three patients had been dosed in an ongoing Phase 2 study of HUYABIO’s novel drug for pharmacological cardioversion of atrial fibrillation (AF). Dr. Mireille Gillings, President, CEO & Executive Chair, said, “We are excited to proceed with…

Read More

Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines

06/20/2022

Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data Excerpt from the Press Release: Agilent Technologies Inc. (NYSE: A), a global leader in genomics technology, today announced it will use Amazon Elastic Compute Cloud (Amazon EC2) G5g instances powered by Amazon Web Services (AWS)…

Read More

Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

06/17/2022

Cemdisiran Treatment Resulted in a 37 Percent Mean Reduction in 24-Hour Urine Protein to Creatinine Ratio, Relative to Placebo – a Key Prognostic Marker of Progression to End-Stage Kidney Disease in Patients with IgA Nephropathy – – Acceptable Safety Profile, Supporting Continued Clinical Development – – Full Results to Be Presented at Future Medical Congress –…

Read More

Cend Therapeutics Announces First Patient Treated in Phase 2b Trial of CEND-1 led by Australasian Gastro-Intestinal Trials Group

06/17/2022

Excerpt from the Press Release: SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) — Cend Therapeutics, Inc. (“Cend”) today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend’s lead investigational drug, in patients with first-line metastatic pancreatic ductal adenocarcinoma. The ASCEND trial is a 125-patient, double-blind, randomized, placebo-controlled clinical…

Read More

Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)

06/07/2022

Open-Label Trial in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the first patient has been dosed in an open-label Phase 2 study evaluating ENV-101 (taladegib)…

Read More

Biora Therapeutics Shares Data Presented at Digestive Disease Week 2022

06/06/2022

Patient Data Suggests Multiple Additional Inflammatory Pathways, Supporting Potential Need for Combination Therapy for Ulcerative Colitis Patient Data Establishes Proof of Concept for Microbiome Sampling Capsule Excerpt from the Press Release: SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared two posters…

Read More

Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting

06/01/2022

– Pharmacokinetic profile supports potential for once-daily dosing in moderate-to-severe psoriasis – – Wide range of doses explore higher ranges of TYK2 inhibition in the clinic than reported by other agents – Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its…

Read More